
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc. is positioned favorably due to its innovative antibody candidates, specifically PEMGARDA, which continues to demonstrate stable neutralizing activity against the currently dominant SARS-CoV-2 variants, suggesting a strong potential for sustained utility in high-risk populations, including immunocompromised individuals. The company’s robust Phase 3 data support a positive long-term outlook, while the expected launch trajectory for PEMGARDA is anticipated to improve in 2025 as providers gain clarity on its protective benefits. Additionally, Invivyd's ongoing commitment to address the needs of immunocompromised patients through the acceleration of its next-generation monoclonal antibody, VYD2311, further enhances the company's potential for revenue growth in a dynamic viral landscape.
Bears say
Invivyd Inc. faces significant challenges following the FDA's rejection of its request to expand the Emergency Use Authorization for PEMGARDA, highlighting the difficulties the company encounters in securing approvals for COVID-19 therapeutics. The setback not only diminishes the potential revenue from a broader treatment application but also emphasizes the need for Invivyd to diversify its pipeline in order to sustain long-term growth in a transitioning market. Additionally, the rejected submission for pemivibart indicates that despite promising clinical data, regulatory hurdles remain substantial, potentially impacting the company's overall valuation and future development prospects.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares